EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A novel long-acting relaxin-2 fusion, AZD3427, improves cardiac performance in non-human primates with cardiac dysfunction

Monika Papworth, Spoorthy Kulkarni, Madeleine Antonsson iD, Isabelle Sermadiras, Daniel Hovdal, Kathleen Connolly, Jan Olsson, Animesh Shukla, Peter Cotton, Magnus Althage, Judy Paterson, Esther Martin und 14 weitere

Cardiovascular Research · 2025

DOI: 10.1093/cvr/cvaf031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Research, 2025. Verfasst von Monika Papworth und 25 weiteren Autor:innen. Beteiligte Einrichtung: Biologics Engineering, Oncology R&D, AstraZeneca, Cambridge, UK. Hauptthemen laut MEDLINE: Relaxin, Recombinant Fusion Proteins, Ventricular Function, Left. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Relaxin-2, a well-known human hormone primarily associated with pregnancy, has shown promising cardiovascular benefits in both pre-clinical models and clinical trials. However, its therapeutic potential has been limited due to the short half-life and the short duration of treatment. To address this, we developed AZD3427, a novel long-acting relaxin-2 analogue, and assessed its efficacy during prolonged treatment in a large animal model with cardiac dysfunction. Methods and results Extensive protein engineering resulted in AZD3427, a novel fusion protein, which closely mimics the natural hormone's structure and consists of a single relaxin-2 and the Fc fragment of human IgG1 to extend its half-life. AZD3427 exhibits an improved pharmacokinetic profile, allowing for weekly or less frequent, subcutaneous dosing, and maintains the pharmacology profile of relaxin-2 with signalling via relaxin family peptide receptor 1 (RXFP1) in cell systems. The effects of chronic RXFP1 agonism with AZD3427 were investigated in a non-human primate (NHP) model with systolic dysfunction and metabolic syndrome. Administration of AZD3427 over a 21-week period led to significant improvements in cardiac function, as evidenced by increased ejection fraction, cardiac output, and stroke volume, as well as reduced systemic vascular resistance. Importantly, no adverse events related to treatments were observed and there were no concomitant changes in heart rate or blood pressure. During the 18-week washout period, the observed effects gradually disappeared.

Conclusion

Prolonged administration of AZD3427, a long-acting relaxin receptor RXFP1 agonist, resulted in remarkable improvement in cardiac function in a NHP model. Findings of this study are an important translational step to developing future therapies and support further clinical development of AZD3427 as a novel treatment for patients with heart failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RelaxinRecombinant Fusion ProteinsVentricular Function, LeftAnimalsDisease Models, AnimalReceptors, G-Protein-CoupledHumansMaleFemaleSignal TransductionReceptors, PeptideMacaca fascicularisTime FactorsStroke VolumeMacaca mulattaImmunoglobulin Fc Fragments

Stichwörter der Autor:innen

AZD3427Heart failureNon-human primateRXFP1Relaxin-2

Substanzen

RelaxinReceptors, G-Protein-CoupledRecombinant Fusion ProteinsReceptors, PeptideRLN2 protein, humanRXFP1 protein, humanImmunoglobulin Fc Fragments

Autor:innen und Institutionen

  • Biologics Engineering, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Department of Medicine, University of Cambridge, Cambridge, UK.
  • Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, USA.

ORCID-Profile: Madeleine Antonsson, Karin Jennbacken

Förderung

  • AstraZeneca

Zitieren

APA

Papworth, M., Kulkarni, S., Antonsson, M., Sermadiras, I., Hovdal, D., Connolly, K., Olsson, J., Shukla, A., Cotton, P., Althage, M., Paterson, J., Martin, E., Wolny, M., Ferraro, F., Sadowska, A., Hao, W., Larsson, N., Backmark, A., Marlow, T., …, & Jennbacken, K. (2025). A novel long-acting relaxin-2 fusion, AZD3427, improves cardiac performance in non-human primates with cardiac dysfunction. Cardiovascular Research. https://doi.org/10.1093/cvr/cvaf031

Vancouver

Papworth M, Kulkarni S, Antonsson M, Sermadiras I, Hovdal D, Connolly K, et al. A novel long-acting relaxin-2 fusion, AZD3427, improves cardiac performance in non-human primates with cardiac dysfunction. Cardiovascular Research. 2025. doi:10.1093/cvr/cvaf031

BibTeX
@article{Papworth2025,
  author = {Papworth, Monika and Kulkarni, Spoorthy and Antonsson, Madeleine and Sermadiras, Isabelle and Hovdal, Daniel and Connolly, Kathleen and Olsson, Jan and Shukla, Animesh and Cotton, Peter and Althage, Magnus and Paterson, Judy and Martin, Esther and Wolny, Marcin and Ferraro, Franco and Sadowska, Agnieszka and Hao, Weidong and Larsson, Niklas and Backmark, Anna and Marlow, Tom and Perez, Rosario and Jermutus, Lutz and Omar, Sami and George, Richard T and Gabrielsen, Anders and Pettersen, Daniel and Jennbacken, Karin},
  title = {A novel long-acting relaxin-2 fusion, AZD3427, improves cardiac performance in non-human primates with cardiac dysfunction},
  journal = {Cardiovascular Research},
  year = {2025},
  doi = {10.1093/cvr/cvaf031}
}
Kostenlos starten →